Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H24O7 |
| Molecular Weight | 388.4111 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@H](C)C(=O)O[C@@H]1[C@H](OC(C)=O)C2=C3OC(=O)C=CC3=CC=C2OC1(C)C
InChI
InChIKey=GVBNSPFBYXGREE-CXWAGAITSA-N
InChI=1S/C21H24O7/c1-6-11(2)20(24)27-19-18(25-12(3)22)16-14(28-21(19,4)5)9-7-13-8-10-15(23)26-17(13)16/h7-11,18-19H,6H2,1-5H3/t11-,18-,19-/m1/s1
| Molecular Formula | C21H24O7 |
| Molecular Weight | 388.4111 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Visnadine is a natural product extracted from the seeds and aerial parts of Ammi visnaga (Umbelliferae), plant widely used in Egyptian medicine since the Pharaohs times as antispastic and for the treatment of angina pectoris and other cardiovascular diseases. It has been used since a long time in western medicine for the treatment of various cardiac diseases and peripheral vasculopathies. Visnadine seems
to act by inhibiting the contractile responses mediated by
Ca2+ entry through L-type Ca2+ channels.Topical use of Visnadine may increase regional vascularization afecting turgidity and sensorial threshold
of the area of application. A formulation for vulvar application
(ReFeel® spray, IDI Integratori Dietetici Italiani S.r.l.,
Italy) has been developed and it contains Visnadine
at high concentration (1%) with an elevate purity index
(minimum 95%). Visnadine spray displayed positive effects on sexual function in women with and without FSD and it was well tolerated. Topical Visnadine may not only be part of multimodal strategies to manage clinically relevant sexual symptoms but also simply to help women to enhance their subjective impaired perception of sexual response.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095177 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9225605 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | ReFeel Approved UseAtrophy of the female external genitalia |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03281655
15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
Route of Administration:
Vaginal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9225605
Visnadine (< 10(-5) M) selectively inhibited the contractions induced by depolarization with 80 mM KCl or by CaCl2 in rat KCl-depolarized aorta and the spontaneous activity of the portal vein. At concentrations higher than 10(-5) M, visnadine also inhibited the contractile responses induced by noradrenaline and phorbol 12-myristate 13-acetate (PMA), being equipotent to inhibit noradrenaline-induced contractions in either Ca(2+)-containing or Ca(2+)-free medium and PMA-induced contractions.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:06:09 GMT 2025
by
admin
on
Mon Mar 31 18:06:09 GMT 2025
|
| Record UNII |
0RL4V0K263
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
C04AX24
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
||
|
WHO-VATC |
QC04AX24
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3649
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
207-515-1
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
100000079325
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104448
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
C067604
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
DTXSID301023583
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
C87287
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
VISNADINE
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
SUB00083MIG
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
442151
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
m11478
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | Merck Index | ||
|
1832
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
0RL4V0K263
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
477-32-7
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY | |||
|
DB13355
Created by
admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |